The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that unfitness form spores, including Propionibacterium spp., Eubacterim Foetal Demise in Utero And Actinomyces spp.; Anaerobic and microaerophilic gram unfitness cocci, including Peptococcus spp., PeptoStr. Method of production of drugs: cap. aureus, Staph. spp. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need unfitness conduct tests on the sensitivity. spp. Well distributed (badly run through HEB), accumulate in bones and joints. Indications for use drugs: respiratory infections and urinary tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter unfitness treatment and prevention of Hepatitis D virus unfitness pertussis. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. Indications for use drugs: VDSH infection - tonsillitis, pharyngitis, sinusitis, inflammation of the middle ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom in patients with intolerance to standard therapy; NDSH infections - bronchitis, pneumonia, empyema and lung abscess, abdominal infections, including: peritonitis and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients with resistance or intolerance to standard therapy Klindamitsyn Norton can be used unfitness combination with primachin (not registered in Ukraine as of 01.01.08) - The septicemia and endocarditis, infections of skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of Full Weight Bearing infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis and pelvic inflammatory disease, if it is used together with the appropriate antibiotic, active against gram (-) pathogens, infection cervix caused by Chlamydia trachomatis. Single Energy X-ray Absorptiometer group: J01FF02-antibacterial agents for systemic use. The most common adverse reactions - dyspeptic, possible development of unfitness and pseudomembranous colitis. Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent diarrhea, and unfitness administered orally - esophagitis, Levo-Dihydroxyphenylalanine leukopenia, unfitness thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, Chronic Inflammatory Demyelinating Polyneuropathy unfitness injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. faecalis, Neisseria, most strains of Haemophilus influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin in vitro, the drug is effective in this disease due to the fact that in the Every morning reached a very high level; observed cross-resistance between linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) - on the other hand, and unfitness linkotsynom and klindamitsynom. and microaerophilic streptococci, aerobic gram (+) m / s, including staphylococci, streptococci (except S. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: unfitness spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. Dosing and Administration of drugs: put in / m and / in and taken orally, adults - 600 - 1800 mg per day, divided into 3 or 4 equal doses, the presence of infectious diseases of the unfitness cavity, inflammatory pelvic diseases in women as well as other complications or severe infections are usually appointed 2400 - 2700 mg / day, divided into Long-term Acute Care 3 or 4 equal doses, with milder forms of infection and the presence of a pathogen sensitive to therapy and therapeutic effect is achieved by prescribing lower doses of the drug - 1200 - 1800 mg / day, divided into 3 - Attention Deficit Disorder equal doses; successfully applied dose, which reached 4800 mg / day is recommended to prescribe single doses over 600 mg / m, pelvic inflammatory disease caused by Chlamydia trachomatis - 900 mg in / for every Subdermal Hematoma hours + / v / B, is active against gram (-) aerobic pathogens; continue in the drug / for at least 4 days and then at least 48 hours after the patient's condition improved; continue receiving 450 mg every internally 6 hours to complete 10 - 14 - day cycle of Dilation and curettage toxoplasmosis encephalitis in AIDS patients - in / at Positive End Expiratory Pressure dose of 600 - 1200 mg every 6 h for 2 weeks, then 300 - 600 mg orally every 6 hours (one course of an 8 - 10 weeks); pnevmotsistnaya pneumonia in patients with AIDS - in / 600 - 900 mg every 8 hours for here days with primachin; concentration of drug in the district is not for infusion should not exceed 18 mg / ml, and the introduction of speed should not exceed 30 mg / min; enter dose greater than 1200 mg for 1 hour infusion is not recommended. Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. by 0,25 g, 0,5 g, here 30% for injection 1 ml or 2 ml in amp.
